Memory Disorders Clinical Trials

Stanford Memory Disorders Clinical Trials

Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Safety, Tolerability, and Efficacy of BIIB092 in Subjects with Mild Cognitive Impairment Due to Alzheimer’s Disease or With Mild Alzheimer’s Disease (NCT03352557)
Status: Active, Enrolling
PI: Sharon J. Sha, MD MS

Research Coordinator: Jenn Gaudioso
Contact: Jenn.gaudioso@stanford.edu

A Phase II, Multicenter, Randomized, Double Blind, Placebo Controlled, Parallel Group, Efficacy, And Safety Study of MTAUtau9937Aa In Patients with Prodromal to Mild Alzheimer’s Disease (NCT03289143)
Status: Active, Enrolling
PI: Sharon J. Sha, MD MS

Research Coordinator: Jenn Gaudioso
Contact: Jenn.gaudioso@stanford.edu

A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study to Evaluate the Efficacy and Safety of E2609 in Subjects with Early Alzheimer’s Disease (NCT02956486)
Status: Active, Enrolling
PI: Sharon J. Sha, MD MS

Research Coordinator: Hanna Balcha
Contact: Hannafb@stanford.edu

A Randomized, Double-Blind, Placebo-Controlled, Two-Cohort Parallel Group Study to Evaluate the Efficacy of CAD106 and CNP520 in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer’s Disease (NCT02565511)
Status: Active, Enrolling
PI: Sharon J. Sha, MD MS

Research Coordinator: Hanna Balcha and Amanda Ng
Contact: Amandang@stanford.edu and Hannafb@stanford.edu

A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of CNP520 in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer’s Disease (NCT03131453)
Status: Active, Enrolling
PI: Sharon J. Sha, MD, MS

Research Coordinator: Hanna Balcha and Amanda Ng
Contact: Amandang@stanford.edu and Hannafb@stanford.edu

Multiple Dose Study of BIIB037 (Recombinant, Fully Human Anti-Aβ IgG1 mAb) in Participants with Prodromal or Mild Alzheimer's Disease. (NCT01677572)
Status: Active, Closed to Enrollment
PI: Sharon J. Sha, MD MS

A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Aducanumab (BIIB037) in Subjects with Early Alzheimer's Disease (NCT02484547)
Status: Active, Closed to Enrollment
PI: Sharon J. Sha, MD MS

A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy and Safety Study of Crenezumab in Patients with Prodromal to Mild Alzheimer's Disease (NCT02670083)
Status: Active, Closed to Enrollment
PI: Sharon J. Sha, MD MS

Clinical trials contacts

memoryresearch@stanford.edu
(650) 724-8736

Sharon Sha, MD, MS
Clinical Assistant Professor, Neurology & Neurological Sciences
Director, Memory Disorders Clinical Trials
ssha1@stanford.edu
(650) 723-5072